Dutch gene therapy developer uniQure today announced the US Food and Drug Administration (FDA) has accepted for review the ...

Germany’s Fresenius has entered an exclusive development agreement with WuXi Biologics, a leading Chinese global contract ...

Henlius Biotech and Accord Healthcare have announced results from ASTRIDE, a randomized, open-label US bridging study of serplulimab (Hetronifly) in extensive-stage small cell lung cancer (ES-SCLC).

Israeli drugmaker Teva Industries said it will discontinue its Phase II TOPAS-MSA study of emrusolmin (TEV-‘286) in adults with multiple system atrophy (MSA), after an interim analysis indicated a ...

The US Food and Drug Administration (FDA) today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for ...

October produced 12 deals in The Pharma Letter ’s coverage, four of them worth more than $1 billion.

Norwegian health officials outlined efforts to reduce drug-related harm through shared patient records and updated prescribing guidance at an industry meeting that also examined the risks of ...

US biotech company Regeneron reported third-quarter 2026 revenues of $5.12 billion, up 36% year-on-year from $3.75 billion and well ahead of analyst consensus of roughly $4.6 billion.

Privately-held Italian drugmaker Alfasigma has announced that the European Commission (EC) has granted marketing authorization for linerixibat in the European Union for the treatment of cholestatic ...

Swiss pharma major Novartis (NOVN: VX) has ended a collaboration with Swedish biotech company BioArctic (Nasdaq Stockholm: BIOA B) aimed at developing a potential brain-penetrant treatment for ...

Sun Pharmaceutical Industries, the Indian pharma major, said the US Food and Drug Administration (FDA) has approved Ilumya (tildrakizumab-asmn), an IL-23 inhibitor, for adults with active psoriatic ...